Form D · Biotechnology
Sofregen Medical Inc.
Medford, MA · CIK 0001685282
Offering snapshot reported Sep 3, 2019 · SEC filing
- Reported sold
- $8.1M Offering amount: $8.1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 16, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 3, 2019 | Initial | $8,104,666 | No comparison | 3 | SEC filing |
| Sep 27, 2017 | Amendment | $9,700,005 | $3,500,000vs Sep 27, 2016 | 7 | SEC filing |
| Sep 27, 2016 | Initial | $6,200,005 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-347870
Source: Form D, filed Sep 3, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anh Hoang | Executive |
| Anh Hoang Lindsay | Director |
| Milan Kofol | Executive |
| Amir Nashat | Director |
| Doug Sheldon | Director |
| S. Douglas Sheldon | Director |
| Howard Weisman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Boston Avenue, Suite 1100
Medford, MA, 02155
Medford, MA, 02155